Outlook Therapeutics Aktie
WKN DE: A2PF3C / ISIN: US69012T2069
08.04.2025 15:10:19
|
Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD
(RTTNews) - Outlook Therapeutics, Inc. (OTLK) Tuesday said it has resubmitted the Biologics License Application (BLA) for ONS-5010 for the treatment of wet age-related macular degeneration or wet AMD.
The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date or a date on which a decision from the regulator is expected, on August 27, 2025.
The BLA resubmission was based on data from NORSE EIGHT study as well as additional chemistry, manufacturing and controls (CMC) information requested by the FDA.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Outlook Therapeutics Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |